Open Trials

At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.  As a member of US Oncology Research and as a clinical research affiliate of VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.
 

BREAST CANCER - ADJUVANT

USOR 20-210

Phase 4, Observational Breast Cancer Study for stage I-III hormone receptor-positive (HR+) breast cancer that has taken adjuvant endocrine therapy for 4-7 years. Breast Cancer Index (BCI) Registry Study. Click here to learn more

BREAST CANCER – METASTATIC

USOR 21380

Phase 3, double-blind, randomized, placebo-controlled study of abemaciclib + fulvestrant versus placebo + fulvestrant for patients with hormone receptor-positive, HER2 negative, who have progressed after prior treatment with CDK4 & 6 inhibitor and endocrine therapy.  Click here to learn more

NRG-BR004

Phase 3, randomized, double-bind study of taxane/trastuzumab/pertuzumab with atezolizumab or placebo in first-line HER2-Positive metastatic breast cancer.  Click here to learn more

COLORECTAL

A021703 (SOLARIS)

Phase 3, randomized, double-blind study of Vitamin D3 supplementation in patients with previously untreated metastatic colorectal cancer. Click here to learn more

A221805 

Phase 2/3, randomized, double-blind, placebo-controlled study of duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy. Click here to learn more

LUNG –  METASTATIC

USOR 21-378

Phase 3, open-label, randomized study of sacituzumab govitecan versus docetaxel in patients with advanced or metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. Click here to learn more

SOLID TUMOR

USOR 21-236

Detecting cancers earlier through elective plasma-based CancerSEEK testing. Patients age 50 years old or greater with untreated solid tumors will undergo one-time blood draw to obtain clinically characterized, whole blood specimens from cancer subjects to develop and refine assays for cancer in the blood.